A Phase 3, randomized study to assess the efficacy and safety of Ublituximab in combination with Ibruninib compared to Ibrutinib alone, in patients with previously treated high-risk Chronic Lymphocytic Leukemia (CLL)

The purpose of the study is to determine how effective the combination of an investigational new drug (ublituximab) and another currently FDA approved drug ibrutinib (also referred to as Imbruvica) is when given to human patients.

Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.

For more information about this study: